Please assess the completion status of the following clinical trial:

Trial Title: A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Be scheduled for a catheter ablation procedure for non-valvular atrial fibrillation (NVAF);~* Have a documented history of paroxysmal (lasting \<1 week) or persistent (lasting \>1 week and \<1 year or requiring pharmacological or electrical cardioversion), or long standing persistent (\>=1 year) NVAF;~* Be suitable for anticoagulant therapy and catheter ablation as per the judgment of the investigator;~* Women must be postmenopausal before entry or practicing a highly effective method of birth control when heterosexually active;~* Women of childbearing potential must have a negative serum pregnancy test at screening;~* Be willing and able to adhere to the prohibitions and restrictions specified in the study protocol;~* Have a life expectancy of at least 6 months~Exclusion Criteria:~* Has a history of a prior stroke, transient ischemic attack (TIA) or non-convulsive status epilepticus within 6 months of the screening visit;~* Has a history of a major bleeding or thromboembolic event within the 12 months immediately preceding the catheter ablation procedure;~* Has had major surgery (requiring general anesthesia), within 6 months before screening or planned surgery during the time the subject is expected to participate in the study;~* Has NVAF due to electrolyte imbalance, hyperthyroidism, or other reversible or noncardiac cause of NVAF;~* Has any condition that, in the opinion of the investigator, would make participation not be in the best interest (eg, compromise the well-being) of the participant or that could prevent, limit, or confound the protocol-specified assessments

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- rivaroxaban (Type: EXPERIMENTAL): rivaroxaban 20 mg orally, once-daily, administered preferably with the evening meal
- vitamin K antagonist (VKA) (Type: EXPERIMENTAL): dose-adjusted vitamin K antagonist (VKA) to achieve a recommended International Normalized Ratio (INR) of 2.0 to 3.0

Based on this trial design, predict the completion outcome and termination type (if applicable).